There have been multiple accounts created with the sole purpose of posting advertisement posts or replies containing unsolicited advertising.

Accounts which solely post advertisements, or persistently post them may be terminated.

Shard ,

How do we know this isn’t some over hyped pop sci article or another Theranos?

stevedidWHAT ,
@stevedidWHAT@lemmy.world avatar

….wonder what the privacy policy is like. Your iris is one of few unique biometric signatures your body has.

autotldr Bot ,

This is the best summary I could come up with:

Its main product is a non-invasive, AI-powered retina scan and technology platform it calls CLAiR, which can detect cardiovascular risks and related diseases such as stroke, type 2 diabetes.

The platform is groundbreaking in its approach: CLAiR uses AI to “read” tiny signals from the blood vessels captured in the retinal images, and Toku claims that it can calculate heart disease risk, hypertension, or high cholesterol in 20 seconds.

The company raised an $8 million Series A funding round earlier this year from U.S. optical retailer National Vision and Japanese firm Topcon Healthcare.

The U.S. Food and Drug Administration (FDA), earlier this month, granted “breakthrough device status” to CLAiR, which can run on existing retinal imaging cameras.

If ultimately cleared and accredited by the FDA, the startup claims it will be the first medical device company in the U.S. to offer an affordable, non-invasive way to detect the risk of CVD using the image of the retina located in the back of the eye.

Toku’s typical end-users will be asymptomatic adults with routine eye exams: the plan is to deploy it at retail optometry, primary care offices, ophthalmology clinics, and pharmacies equipped with retinal cameras.

The original article contains 854 words, the summary contains 194 words. Saved 77%. I’m a bot and I’m open source!

  • All
  • Subscribed
  • Moderated
  • Favorites
  • •
  • [email protected]
  • random
  • lifeLocal
  • goranko
  • All magazines
    •